Glucagon-like peptide-1 receptor agonists (also known as GLP-1 receptor agonists, GLP-
1DAs, incretin mimetics, or GLP-1 analogs)) are a class of medications utilized in the …

Over the last decade, the discovery of glucagon-like peptide 1 receptor agonists (GLP-1
RAs) has increased the treatment options for patients with type 2 diabetes mellitus (T2DM) …

Background Glucagon-like peptide-1 receptor agonists (GLP-1RAs) act by increasing insulin
secretion, decreasing glucagon secretion, slowing gastric emptying, and increasing satiety …

Abstract Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RAs) are injectable
glucose-lowering medications approved for the treatment of adult patients with type 2 …

More than 26 million people in the United States have type 2 diabetes mellitus (T2D). Many
treatment options exist, but achieving long‐term glycemic control in patients with T2D …

This communication provides a contemporary classification of glucagon-like peptide 1
receptor agonists (GLP1RAs) based on indication, route, and frequency of administration …

Glucagon-like peptide-1 receptor analogues/agonists (GLP-1RAs) are well established as
effective adjuncts to lifestyle modification in the treatment of type 2 diabetes (T2D) as …

The incretin system is an area of great interest for the development of new therapies for the
management of type 2 diabetes. Existing antidiabetic drugs are often insufficient at getting …

Current management options for treating type 2 diabetes are diverse. Many different classes
of antidiabetes therapies are used in clinic, and several new candidates are in late-phase …

ABSTRACT Glucagon-like peptide-1 (GLP-1) is a hormone of the incretin system
responsible for a variety of glucoregulatory effects, including glucose-dependent secretion of …